Corline Biomedical AB Profit Margin

Corline Biomedical AB (CLBIO.ST) currently reports a profit margin of -99.48% as of June 2026. That compares with -292.68% in the prior-year period — up 66.0% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Corline Biomedical AB's profit margin history and peer comparisons.

Corline Biomedical AB's profit margin increased from -292.68% to -99.48% — a 66.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Corline Biomedical AB's profit margin of -99.48% is lower than the Healthcare sector average of 9.48%. That is roughly 1149.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Corline Biomedical AB's current -99.48% should be judged against Healthcare norms (sector average: 9.48%) and against CLBIO.ST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -99.48%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Corline Biomedical AB, and consider following CLBIO.ST for alerts when major investors trade the stock.